[
  {
    "ts": null,
    "headline": "Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing",
    "summary": "The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.",
    "url": "https://finnhub.io/api/news?id=7fe7ec424e0631289a4f9fbffb6ee9109932692a44ab8046216b5d4923f3e5cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745431302,
      "headline": "Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing",
      "id": 134046234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.",
      "url": "https://finnhub.io/api/news?id=7fe7ec424e0631289a4f9fbffb6ee9109932692a44ab8046216b5d4923f3e5cc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly is stepping up its fight against copycat weight loss drugs",
    "summary": "In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.",
    "url": "https://finnhub.io/api/news?id=f126f4a82d1dbadaad43371a861e776a56878b017ec669cea5d8fac8706cd1e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745424840,
      "headline": "Eli Lilly is stepping up its fight against copycat weight loss drugs",
      "id": 134046235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.",
      "url": "https://finnhub.io/api/news?id=f126f4a82d1dbadaad43371a861e776a56878b017ec669cea5d8fac8706cd1e9"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'",
    "summary": "All three major US stock indexes were up sharply, with the Nasdaq Composite gaining nearly 3% in lat",
    "url": "https://finnhub.io/api/news?id=0d0a3314a49af396408734d9c53dde14f07e670204d7aec83fbdb856c046d400",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745424164,
      "headline": "Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'",
      "id": 134046236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up sharply, with the Nasdaq Composite gaining nearly 3% in lat",
      "url": "https://finnhub.io/api/news?id=0d0a3314a49af396408734d9c53dde14f07e670204d7aec83fbdb856c046d400"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?",
    "summary": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming […]",
    "url": "https://finnhub.io/api/news?id=41d150d8467940c01796d659fce93aff5c1b99a817c900a5a58660838490cd85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745417933,
      "headline": "Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?",
      "id": 134046237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming […]",
      "url": "https://finnhub.io/api/news?id=41d150d8467940c01796d659fce93aff5c1b99a817c900a5a58660838490cd85"
    }
  },
  {
    "ts": null,
    "headline": "Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug",
    "summary": "Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year.  This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023.  Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly.",
    "url": "https://finnhub.io/api/news?id=734c87b8fa30b8adf3c44a145a15c9fab121139d3006e1e8501f84e3a64831fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745416380,
      "headline": "Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug",
      "id": 134046238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year.  This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023.  Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly.",
      "url": "https://finnhub.io/api/news?id=734c87b8fa30b8adf3c44a145a15c9fab121139d3006e1e8501f84e3a64831fc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle",
    "summary": "Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle",
    "url": "https://finnhub.io/api/news?id=15b32c0c3a510d3b5de081085e51fc0a0343dcf4a6fe0cf9a3ff58cb7785db4a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745416353,
      "headline": "Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle",
      "id": 134045691,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=15b32c0c3a510d3b5de081085e51fc0a0343dcf4a6fe0cf9a3ff58cb7785db4a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Widens Legal War Against Other Weight-Loss Drug Sellers",
    "summary": "By Dean Seal Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and...",
    "url": "https://finnhub.io/api/news?id=c21c3cddb427b3077a3591c0964d25da2add7276762adab2599229031cbef51e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745406607,
      "headline": "Eli Lilly Widens Legal War Against Other Weight-Loss Drug Sellers",
      "id": 134044686,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Dean Seal Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and...",
      "url": "https://finnhub.io/api/news?id=c21c3cddb427b3077a3591c0964d25da2add7276762adab2599229031cbef51e"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.",
    "summary": "Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant.  On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly.  While Seigerman waxed bullish about the company's hottest product at the moment (obesity drug Zepbound), he expressed concerns about the broader macroeconomic environment.",
    "url": "https://finnhub.io/api/news?id=e753a0f19d54520681bfd76b9b33a9a765184f7798ba95f58651389b12488990",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745405700,
      "headline": "Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.",
      "id": 134046239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant.  On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly.  While Seigerman waxed bullish about the company's hottest product at the moment (obesity drug Zepbound), he expressed concerns about the broader macroeconomic environment.",
      "url": "https://finnhub.io/api/news?id=e753a0f19d54520681bfd76b9b33a9a765184f7798ba95f58651389b12488990"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds",
    "summary": "Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.Lilly is suing Mochi...",
    "url": "https://finnhub.io/api/news?id=0950c7fe5f3d727965d909858694b39a3f95201d13b362b3ab3049e0f4cfa865",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745404806,
      "headline": "Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds",
      "id": 134044479,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.Lilly is suing Mochi...",
      "url": "https://finnhub.io/api/news?id=0950c7fe5f3d727965d909858694b39a3f95201d13b362b3ab3049e0f4cfa865"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?",
    "summary": "Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year.  Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected.  The company has also faced clinical trial setbacks: An otherwise promising weight loss medicine it developed failed to impress the market with its late-stage results.",
    "url": "https://finnhub.io/api/news?id=9e270e0f6a2ee0c7362d6899984553f8b2c919074f8491948a89d22734327127",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745401800,
      "headline": "Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?",
      "id": 134046240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year.  Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected.  The company has also faced clinical trial setbacks: An otherwise promising weight loss medicine it developed failed to impress the market with its late-stage results.",
      "url": "https://finnhub.io/api/news?id=9e270e0f6a2ee0c7362d6899984553f8b2c919074f8491948a89d22734327127"
    }
  },
  {
    "ts": null,
    "headline": "Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly",
    "summary": "Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly",
    "url": "https://finnhub.io/api/news?id=a79fa8a758843e95364971c73721924e5267126c6685c224691600627ddd165e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745401558,
      "headline": "Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly",
      "id": 134044244,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a79fa8a758843e95364971c73721924e5267126c6685c224691600627ddd165e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly sues four compounders over copies of weight-loss drugs",
    "summary": "Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines. Compounders were, until recently, allowed to produce copies of obesity drugs while the FDA classified them as being in shortage, under U.S. rules that permit such manufacturing only during supply gaps. Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including the blockbuster, Mounjaro.",
    "url": "https://finnhub.io/api/news?id=b931a9f0a055f4ae12318c5a323a5e18fd3453b00598545b8d1d3453143fdc12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745399685,
      "headline": "Lilly sues four compounders over copies of weight-loss drugs",
      "id": 134059254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines. Compounders were, until recently, allowed to produce copies of obesity drugs while the FDA classified them as being in shortage, under U.S. rules that permit such manufacturing only during supply gaps. Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including the blockbuster, Mounjaro.",
      "url": "https://finnhub.io/api/news?id=b931a9f0a055f4ae12318c5a323a5e18fd3453b00598545b8d1d3453143fdc12"
    }
  },
  {
    "ts": null,
    "headline": "Polen Focus Growth Portfolio Q1 2025 Commentary",
    "summary": "Polen Focus Growth Portfolio Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=c04a2e189437aa14ee5196a62e1771aeac71d0437b10bfd1f20b731be320ef8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745399400,
      "headline": "Polen Focus Growth Portfolio Q1 2025 Commentary",
      "id": 134043992,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c04a2e189437aa14ee5196a62e1771aeac71d0437b10bfd1f20b731be320ef8e"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Buy?",
    "summary": "The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.",
    "url": "https://finnhub.io/api/news?id=ef8f5eafabf730d3623cb4509354d464b5494f8bcd952450ce612cb8d11bf560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745399220,
      "headline": "Is Eli Lilly Stock a Buy?",
      "id": 134046242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.",
      "url": "https://finnhub.io/api/news?id=ef8f5eafabf730d3623cb4509354d464b5494f8bcd952450ce612cb8d11bf560"
    }
  },
  {
    "ts": null,
    "headline": "The Ithaka Group Q1 2025 Commentary",
    "summary": "The Ithaka Group Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=05d3a414160810b61e927072d27fe0aa78b65e1132c54968758e195c92b98227",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745399100,
      "headline": "The Ithaka Group Q1 2025 Commentary",
      "id": 134043933,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=05d3a414160810b61e927072d27fe0aa78b65e1132c54968758e195c92b98227"
    }
  },
  {
    "ts": null,
    "headline": "Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF",
    "summary": "Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF",
    "url": "https://finnhub.io/api/news?id=4e2895c60172ec813669e7720e27eae672d770862365721c520ab9af6a0689a7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745387465,
      "headline": "Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF",
      "id": 134042530,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4e2895c60172ec813669e7720e27eae672d770862365721c520ab9af6a0689a7"
    }
  }
]